These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19254842)

  • 21. A three-dimensional pharmacophore modelling of ITK inhibitors and virtual screening for novel inhibitors.
    Bagga V; Silakari O; Ghorela VS; Bahia MS; Rambabu G; Sarma J
    SAR QSAR Environ Res; 2011 Mar; 22(1-2):171-90. PubMed ID: 21391146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2.
    Xie QQ; Xie HZ; Ren JX; Li LL; Yang SY
    J Mol Graph Model; 2009 Feb; 27(6):751-8. PubMed ID: 19138543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacophore development and screening for discovery of potential inhibitors of ADAMTS-4 for osteoarthritis therapy.
    Verma P; Dalal K; Chopra M
    J Mol Model; 2016 Aug; 22(8):178. PubMed ID: 27401455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
    Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
    Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3D-QSAR-Based Pharmacophore Modeling, Virtual Screening, and Molecular Dynamics Simulations for the Identification of Spleen Tyrosine Kinase Inhibitors.
    Kumar V; Parate S; Danishuddin ; Zeb A; Singh P; Lee G; Jung TS; Lee KW; Ha MW
    Front Cell Infect Microbiol; 2022; 12():909111. PubMed ID: 35846777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Orally bioavailable Syk inhibitors with activity in a rat PK/PD model.
    Thoma G; Veenstra S; Strang R; Blanz J; Vangrevelinghe E; Berghausen J; Lee CC; Zerwes HG
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4642-7. PubMed ID: 26320624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
    Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
    J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein kinase B (PKB β) inhibitors.
    Vyas VK; Ghate M; Goel A
    J Mol Graph Model; 2013 May; 42():17-25. PubMed ID: 23507201
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
    J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
    Lovering F; Aevazelis C; Chang J; Dehnhardt C; Fitz L; Han S; Janz K; Lee J; Kaila N; McDonald J; Moore W; Moretto A; Papaioannou N; Richard D; Ryan MS; Wan ZK; Thorarensen A
    ChemMedChem; 2016 Jan; 11(2):217-33. PubMed ID: 26381330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel anaplastic lymphoma kinase (ALK) inhibitors using a common feature pharmacophore model derived from known ligands crystallized with ALK.
    Xie HZ; Lan H; Pan YL; Zou J; Wang ZR; Li LL; Huang Q; Zhang H; Yang SY
    Chem Biol Drug Des; 2013 Feb; 81(2):175-84. PubMed ID: 23107363
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors.
    Sakkiah S; Thangapandian S; John S; Kwon YJ; Lee KW
    Eur J Med Chem; 2010 Jun; 45(6):2132-40. PubMed ID: 20206418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Tang C; Zhu X; Huang D; Zan X; Yang B; Li Y; Du X; Qian H; Huang W
    J Mol Model; 2012 Jun; 18(6):2795-804. PubMed ID: 22120948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applying ligands profiling using multiple extended electron distribution based field templates and feature trees similarity searching in the discovery of new generation of urea-based antineoplastic kinase inhibitors.
    Dokla EM; Mahmoud AH; Elsayed MS; El-Khatib AH; Linscheid MW; Abouzid KA
    PLoS One; 2012; 7(11):e49284. PubMed ID: 23185312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly potent aminopyridines as Syk kinase inhibitors.
    Castillo M; Forns P; Erra M; Mir M; López M; Maldonado M; Orellana A; Carreño C; Ramis I; Miralpeix M; Vidal B
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5419-23. PubMed ID: 22877633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
    Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening.
    Gangwal RP; Das NR; Thanki K; Damre MV; Dhoke GV; Sharma SS; Jain S; Sangamwar AT
    J Mol Graph Model; 2014 Apr; 49():18-24. PubMed ID: 24473068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New spleen tyrosine kinase inhibitors: patent applications published during 2011-2013.
    Thorarensen A; Kaila N
    Pharm Pat Anal; 2014 Sep; 3(5):523-41. PubMed ID: 25374321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.